Publications: Gilmore, Grace
2020
Favaloro, E.J., Gilmore, G., Bonar, R., Dean, E., Arunachalam, S., Mohammed, S. and Baker, R. (2020) Laboratory testing for activated protein C resistance: rivaroxaban induced interference and a comparative evaluation of andexanet alfa and DOAC Stop to neutralise interference. Clinical Chemistry and Laboratory Medicine, 58 (8).
Favaloro, E.J., Gilmore, G., Bonar, R., Dean, E., Arunachalam, S., Mohammed, S. and Baker, R. (2020) Reducing the effect of DOAC interference in laboratory testing for factor VIII and factor IX: A comparative study using DOAC Stop and andexanet alfa to neutralize rivaroxaban effects. Haemophilia . Early View.
Tiao, J., Powell, S., Gilmore, G., Veedu, R., Wilton, S. and Baker, R. (2020) Splice inducing Antisense Oligonucleotides as a potential gene correction therapy for haemophilia A. Haemophilia, 26 (S4). pp. 21-22.
2019
Favaloro, E., Gilmore, G., Arunachalam, S., Mohammed, S. and Baker, R. (2019) Neutralising rivaroxaban induced interference in laboratory testing for lupus anticoagulant (LA): A comparative study using DOAC Stop and andexanet alfa. Thrombosis Research, 180 . pp. 10-19.
2006
Adams, M.J.
ORCID: 0000-0002-7743-4515, Thom, J., Hankey, G.J., Baker, R., Gilmore, G., Staton, J. and Eikelboom, J.W.
(2006)
The tissue factor pathway in ischemic stroke.
Blood Coagulation & Fibrinolysis, 17
(7).
pp. 527-532.